Nanofilm Technologies (MZH) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
21 Oct, 2026Executive summary
1H2024 revenue grew 13% YoY to S$82.6m, led by AMBU and NFBU growth, partly offset by IEBU decline.
Adjusted EBITDA rose 61.4% to S$16.7m; margin improved to 20.2% from 14.2%.
Net loss narrowed to S$3.7m from S$7.9m, reflecting improved gross margins and higher adjusted EBITDA.
Interim dividend of 0.33 Singapore cents per ordinary share declared.
Financial highlights
Gross profit rose 18.0% to S$27.7m; gross margin increased to 33.5% from 32.0%.
Administrative expenses fell 3.3% to S$21.2m; staff costs declined S$1.9m, or 5%.
Selling and distribution costs increased 27.7% to S$4.7m, reflecting investment in sales capabilities.
R&D and engineering expenses remained stable, with higher capitalisation as more projects progressed toward commercialisation.
Outlook and guidance
FY2024 revenue and profits expected to exceed FY2023, barring unforeseen circumstances.
2H2024 growth expected from 3C seasonality, delayed project ramps, new customer contributions and improved margins.
Cost optimisation, process streamlining, automation and strategic procurement to continue; full-year capex expected to be lower.
Continued investment in Vietnam and Europe to support China+1 strategy and long-term growth.
Latest events from Nanofilm Technologies
- Capacity investments and segment momentum underpin growth plans amid supply-chain disruption.MZH
Q4 2021 TU - Record FY2021 results and expanded capacity set the stage for FY2022 growth.MZH
H2 2021 - Revenue grew 24.2%, while startup and NPI costs pressured profit and margins.MZH
H1 2021 - 2H recovery lifted earnings and margins, underpinning conditional FY2024 growth expectations.MZH
H2 2023 - Headwinds cut FY2022 results, while expansion and the 2025 targets remained on track.MZH
H2 2022 - Revenue fell 34.4% as consumer weakness drove a H1 loss; 2H revenue is expected higher.MZH
H1 2023 - FY2025 revenue rose 20% and PAT 58%, led by AMBU growth and an IEBU recovery.MZH
H2 2025 - Revenue rose 29.6% as PATMI returned to profit and adjusted EBITDA grew 46.1%.MZH
H1 2025 - Revenue rose 15% and adjusted EBITDA 31%, supported by growth and global expansion.MZH
H2 2024